Literature DB >> 28586094

Disparities in liver cancer occurrence in the United States by race/ethnicity and state.

Farhad Islami1, Kimberly D Miller2, Rebecca L Siegel3, Stacey A Fedewa4, Elizabeth M Ward5, Ahmedin Jemal6.   

Abstract

Liver cancer is highly fatal, and death rates in the United States are increasing faster than for any other cancer, having doubled since the mid-1980s. In 2017, it is estimated that the disease will account for about 41,000 new cancer cases and 29,000 cancer deaths in the United States. In this article, data from the Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics are used to provide an overview of liver cancer incidence, mortality, and survival rates and trends, including data by race/ethnicity and state. The prevalence of major risk factors for liver cancer is also reported based on national survey data from the Centers for Disease Control and Prevention. Despite the improvement in liver cancer survival in recent decades, only 1 in 5 patients survives 5 years after diagnosis. There is substantial disparity in liver cancer death rates by race/ethnicity (from 5.5 per 100,000 in non-Hispanic whites to 11.9 per 100,000 in American Indians/Alaska Natives) and state (from 3.8 per 100,000 in North Dakota to 9.6 per 100,000 in the District of Columbia) and by race/ethnicity within states. Differences in risk factor prevalence account for much of the observed variation in liver cancer rates. Thus, in contrast to the growing burden, a substantial proportion of liver cancer deaths could be averted, and existing disparities could be dramatically reduced, through the targeted application of existing knowledge in prevention, early detection, and treatment, including improvements in vaccination against hepatitis B virus, screening and treatment for chronic hepatitis C virus infections, maintaining a healthy body weight, access to high-quality diabetes care, preventing excessive alcohol drinking, and tobacco control, at both the state and national levels. CA Cancer J Clin 2017;67:273-289.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  United States; cancer stage; death rates; incidence; liver cancer; mortality; surveillance; survival

Mesh:

Year:  2017        PMID: 28586094     DOI: 10.3322/caac.21402

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  79 in total

1.  A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC.

Authors:  Xia Sheng; Yuan Ji; Guo-Ping Ren; Chang-Li Lu; Jing-Ping Yun; Li-Hong Chen; Bin Meng; Li-Juan Qu; Guang-Jie Duan; Qing Sun; Xin-Qing Ye; Shan-Shan Li; Jing Yang; Bing Liao; Zhan-Bo Wang; Jian-Hua Zhou; Yu Sun; Xue-Shan Qiu; Lei Wang; Zeng-Shan Li; Jun Chen; Chun-Yan Xia; Song He; Chuan-Ying Li; En-Wei Xu; Jing-Shu Geng; Chao Pan; Dong Kuang; Rong Qin; Hong-Wei Guan; Zhan-Dong Wang; Li-Xing Li; Xi Zhang; Han Wang; Qian Zhao; Bo Wei; Wu-Jian Zhang; Shao-Ping Ling; Xiang Du; Wen-Ming Cong
Journal:  Hepatol Int       Date:  2020-12-28       Impact factor: 6.047

Review 2.  Roles of mitochondria in liver cancer stem cells.

Authors:  Ching-Wen Chang; Jeng-Fan Lo; Xin Wei Wang
Journal:  Differentiation       Date:  2019-05-30       Impact factor: 3.880

3.  Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes.

Authors:  Ricardo A Franco; Yunhua Fan; Stephanie Jarosek; Sejong Bae; James Galbraith
Journal:  Am J Prev Med       Date:  2018-11       Impact factor: 5.043

Review 4.  MicroRNA regulation of liver cancer stem cells.

Authors:  Weiyang Lou; Jingxing Liu; Yanjia Gao; Guansheng Zhong; Bisha Ding; Liang Xu; Weimin Fan
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

5.  The Effect of 5A nursing intervention on living quality and self-care efficacy of patients undergoing chemotherapy after hepatocellular carcinoma surgery.

Authors:  Xuejuan Zhang; Min Lai; Donghan Wu; Pidan Luo; Shuixi Fu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 6.  The changing landscape of cancer in the USA - opportunities for advancing prevention and treatment.

Authors:  Farhad Islami; Rebecca L Siegel; Ahmedin Jemal
Journal:  Nat Rev Clin Oncol       Date:  2020-05-28       Impact factor: 66.675

Review 7.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

8.  Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons.

Authors:  Meheret Endeshaw; Benjamin D Hallowell; Hilda Razzaghi; Virginia Senkomago; Matthew T McKenna; Mona Saraiya
Journal:  Cancer       Date:  2018-11-27       Impact factor: 6.860

9.  Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey.

Authors:  Sonia A Cunningham; Robert Yu; Tina Shih; Sharon Giordano; Lorna H McNeill; Ruth Rechis; Susan K Peterson; Paul Cinciripini; Lewis Foxhall; Ernest Hawk; Sanjay Shete
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-30       Impact factor: 4.254

10.  YY1-mediated reticulocalbin-2 upregulation promotes the hepatocellular carcinoma progression via activating MYC signaling.

Authors:  Chengjie Mei; Xiang Jiang; Yang Gu; Xiaoling Wu; Weijie Ma; Xi Chen; Ganggang Wang; Ye Yao; Yingyi Liu; Zhonglin Zhang; Yufeng Yuan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.